Oncology
Lantern Pharma Unveils Multi-Agent AI and Computational Biology Tools for withZeta.ai Platform
Lantern Pharma announced the next phase of its withZeta.ai platform, including ZetaSwarm and ZetaOmics, which could accelerate oncology research and create a new revenue stream for the company.
New Study Links Breast Tissue Aging to Increased Breast Cancer Risk in Older Women
Research mapping breast tissue changes with age explains higher breast cancer rates in older women and may guide new treatments.
Telomir Pharmaceuticals Gains FDA Clearance for Telomir-Zn Phase 1/2 Trial in Triple-Negative Breast Cancer
Telomir Pharmaceuticals announced FDA IND clearance for Telomir-Zn to treat advanced triple-negative breast cancer, allowing a Phase 1/2 trial to proceed and marking a key step toward clinical development.
New Molecule Shows Promise for Glioblastoma Treatment, Clinical Trial Underway
Researchers at Brown University Health have identified a molecule that may alter glioblastoma treatment, with a clinical trial planning direct surgical delivery to the tumor.
LIXTE Biotechnology Advances Precision Oncology with Novel PP2A Inhibitor LB-100
LIXTE Biotechnology Holdings is developing LB-100, a first-in-class PP2A inhibitor that enhances chemotherapy and immunotherapy while reducing side effects, with ongoing clinical trials for ovarian and colon cancers.
GeoVax Positions Gedeptin as Immune-Sensitizing Platform Amid Industry Shift to In Vivo Cancer Therapies
GeoVax highlights its gene-directed enzyme prodrug therapy Gedeptin as a potential immune-sensitizing platform that could enhance checkpoint inhibitor efficacy in solid tumors, aligning with rising industry investment in simplified in vivo cancer treatments.
Advanced Heart, Kidney and Metabolic Syndrome Linked to 30% Higher Cancer Risk, Study Finds
New research published in Circulation: Population Health and Outcomes reveals that later stages of cardiovascular-kidney-metabolic (CKM) syndrome are associated with a 25-30% increased risk of cancer, highlighting the need for integrated screening.
LIXTE Biotechnology Advances Precision Cancer Treatment with Novel PP2A Inhibitor
LIXTE Biotechnology is pioneering a new approach in oncology with its lead compound LB-100, which enhances chemotherapy and radiation efficacy while reducing side effects, potentially improving patient outcomes.
Lantern Pharma to Showcase AI Co-Scientist Platform withZeta.ai in Live Public Demo
Lantern Pharma will host its first live demonstration of the withZeta.ai AI co-scientist platform on April 30, 2026, showcasing its ability to accelerate oncology drug discovery and marking a potential new revenue stream through a subscription model.
Oncotelic Therapeutics Highlights Partnership Strategy to Advance Pipeline and Boost Shareholder Value
Oncotelic Therapeutics updates its partnership-driven strategy, citing a $249 million valuation boost from its GMP Biotechnology joint venture and plans for further collaborations to advance its oncology pipeline efficiently.
Oncotelic Therapeutics Featured in BioMedWire Editorial on Biotech Valuation Shift
Oncotelic Therapeutics' inclusion in a BioMedWire editorial highlights how advancing drug pipelines are reshaping biotech valuations, with its AI-driven oncology pipeline and 45% stake in GMP Bio serving as examples of innovation translating into tangible enterprise value.
Canadian Scientists Identify Brain Cells That Fuel Glioblastoma Growth
Researchers have discovered that certain brain cells previously thought to be passive support structures actively promote glioblastoma tumor growth, potentially opening new therapeutic avenues for one of the deadliest forms of brain cancer.
Kairos Pharma Recognized for Innovation in Overcoming Cancer Drug Resistance
Kairos Pharma Ltd. has been honored with the 2026 Pinnacle Award for its pioneering work on resistance-modulating treatments that aim to enhance the effectiveness of existing cancer therapies.
Personalized mRNA Vaccine Shows Promise in Extending Pancreatic Cancer Survival
A personalized mRNA vaccine has demonstrated potential to meaningfully extend survival for pancreatic cancer patients, according to six-year trial results presented at a major oncology conference.
Oncotelic Therapeutics Reports $249 Million Net Income for FY 2025 Driven by Joint Venture Valuation
Oncotelic Therapeutics announced a dramatic financial turnaround with $249 million net income for fiscal year 2025, primarily due to a non-cash gain from its GMP Biotechnology joint venture valuation, signaling potential growth in its oncology and COVID-19 drug pipeline.
Combination Strategies Reshape Precision Oncology as Lixte Advances First-in-Class PP2A Inhibitor
Lixte Biotechnology's LB-100, a first-in-class PP2A inhibitor designed to enhance chemotherapy and immunotherapy, exemplifies the industry shift toward combination regimens to overcome resistance in solid tumors.
Soligenix Reports Encouraging Interim Data and Positive Comparative Results for CTCL Therapy
Soligenix released promising interim analysis from its phase 3 FLASH2 study and positive comparative results for HyBryte versus Valchlor, reinforcing its progress in developing treatments for cutaneous T-cell lymphoma.
Precision Oncology Shifts to Combination Strategies as Resistance Challenges Persist
Cancer treatment is increasingly moving toward multi-drug regimens that combine targeted therapies with immunotherapy and chemotherapy, with Lixte Biotechnology's first-in-class PP2A inhibitor LB-100 designed to enhance existing treatments by disrupting cancer cell repair and boosting immune activity.
Lantern Pharma Seeks FDA Feedback on HARMONIC Trial Protocol Amendments for Lung Cancer Drug
Lantern Pharma has scheduled a Type C meeting with the FDA to discuss proposed changes to its Phase 2 HARMONIC trial for LP-300 in non-small cell lung cancer, focusing on EGFR Exon 21 L858R patients based on promising clinical data.
Aditxt Subsidiary's Protein Analysis Platform Shows Promise in Breast Cancer Treatment Study
A study published in npj Precision Oncology found that Ignite Proteomics' protein analysis platform provided more predictive insight into metastatic breast cancer treatment outcomes than traditional methods, potentially improving treatment selection.
Lantern Pharma Reports Strong Q3 2025 Results with AI-Driven Oncology Pipeline Advances
Lantern Pharma demonstrated significant clinical progress in its AI-driven oncology programs, including successful Phase 1a trial results for LP-184 and regulatory clarity for pediatric CNS cancer development, positioning the company to address multiple high-value cancer markets.
Lantern Pharma CEO Details AI Platform's Role in Accelerating Cancer Drug Development
Lantern Pharma is using artificial intelligence to significantly reduce the time and cost of oncology drug development while expanding treatment options for cancer patients.
Lantern Pharma to Host Q3 2025 Results Webcast, Highlighting AI-Driven Oncology Pipeline
Lantern Pharma will review its third-quarter 2025 financial results and AI platform developments during a November webcast, showcasing how artificial intelligence is accelerating cancer drug discovery and development.
Study Reveals Neurocognitive Decline in CNS Cancer Patients, Highlighting Treatment Challenges
Recent research demonstrates significant neurocognitive decline in central nervous system cancer patients, emphasizing the critical need for therapies that address both tumor control and cognitive preservation.
Kairos Pharma Reports Promising Phase 2 Results for Prostate Cancer Treatment ENV105
Kairos Pharma's ENV105 demonstrates 86% clinical benefit rate in advanced metastatic prostate cancer patients when combined with standard therapy, potentially addressing critical treatment resistance challenges in oncology.
Heidelberg Pharma Reports Promising Clinical Data for Multiple Myeloma Treatment HDP-101
Heidelberg Pharma will present new clinical data showing objective responses and anti-tumor activity in multiple myeloma patients treated with its lead antibody-drug conjugate candidate HDP-101, highlighting its potential to address significant unmet medical needs in relapsed or refractory cases.
Sapu Nano Announces First Human Trial of Injectable Everolimus Formulation for Breast Cancer
Sapu Nano has revealed initial human clinical trials for Sapu-003, an intravenous formulation of Everolimus that could offer improved bioavailability and efficacy compared to oral versions for breast cancer treatment.
Soligenix Strengthens CTCL Advisory Board to Advance HyBryte Therapy Development
Soligenix has updated its U.S. Medical Advisory Board for cutaneous T-cell lymphoma to support the clinical advancement of HyBryte and related therapies, reflecting the company's strategic focus on navigating complex regulatory and commercialization challenges in the rare disease space.
Oncotelic Therapeutics Featured in Editorial on Nanomedicine Advances in Oncology
Oncotelic Therapeutics' inclusion in a NetworkNewsWire editorial highlights how its Deciparticle platform represents significant progress in nanomedicine for improving cancer drug delivery and reducing toxicity.
Helix BioPharma Narrows Losses Amid Strategic Shift to Lung Cancer Focus
Helix BioPharma reported reduced financial losses for fiscal 2025 while implementing a strategic pivot to focus exclusively on developing its L-DOS47 treatment for non-small cell lung cancer in combination with immunotherapy.